Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster Display

1564 - AVAPLUS: Impact of geriatric assessment on first-line treatment duration (TD) and progression free survival (PFS) in mCRC patients ≥ 70 years


08 Oct 2016


Poster Display


Lore Decoster


Annals of Oncology (2016) 27 (6): 149-206. 10.1093/annonc/mdw370


L. Decoster1, C. Kenis2, B. Naessens3, G. Houbiers4, M. De Man5, G. Lambecht6, E. Monsaert7, V. Moons8, P. Vergauwe9, H. Prenen10, E. van Cutsem10, E. Beutels11, D. Frijns12, H. Wildiers2

Author affiliations

  • 1 Medical Oncology, UZ Brussel, 1090 - Brussels/BE
  • 2 Medical Oncology, University Hospitals Leuven - Campus Gasthuisberg, Leuven/BE
  • 3 Gastro-enterology, AZ Nikolaas Hospital, St Niklaas/BE
  • 4 Gastro-enterology, Centre Hospitalier Chrétien (CHC), Liège/BE
  • 5 Gastro-enterology, Gent University Hospital, Gent/BE
  • 6 Gastro-enterology, AZ Damiaan, Oostende/BE
  • 7 Gastro-enterology, AZ Maria Middelares, Gent/BE
  • 8 Gastro-enterology, Imeldaziekenhuis, Bonheiden/BE
  • 9 Gastro-enterology, AZ Groeninge Hospital, Kortrijk/BE
  • 10 Gastro-enterology, University Hospitals Leuven - Campus Gasthuisberg, Leuven/BE
  • 11 Medical Writing, Innosens, Brussels/BE
  • 12 Medical Affairs, ROCHE NV/SA, Brussels/BE


Abstract 1564


Geriatric assessments (GA) allow evaluation of individual global health status and treatment optimisation. This real-life study complements the knowledge on chemotherapy (CT) and bevacizumab usage in elderly with mCRC focussing the impact of geriatric screening and GA on TD, PFS and severe toxicity.


This study included 252 Belgian mCRC patients ≥ 70 years receiving CT with or without bevacizumab. Eastern Cooperative Oncology Group (ECOG), geriatric screening with G8 and Flemish Triage Risk Screening Tool (fTRST), as well as GA including activities of daily living (ADL), instrumental activities of daily living (IADL), Mini-Mental State Examination (MMSE), Geriatric Depression Scale (GDS), Mini Nutritional Assessment (MNA), Charlson Comorbidity Index (CCI), and Mobility-Tiredness Test (Mob-T) was performed in all patients at baseline. For correlations with the different screening and GA components, logrank tests (for TD and PFS), Wilcoxon or Student t-tests (for severe toxicity) and multivariate analyses were used. Additionally, a subgroup analysis excluding patients with ECOG ≥ 2 at baseline was performed.


Median TD (95% CI) was 5.5m (5.1-6.2) in the total safety population. In univariate analysis, ECOG > 1, which was only 14.6% of patients, and MNA were the only baseline parameters significantly associated with TD (p = 0.0006 and p = 0.0162, respectively), while G8 showed a trend (p = 0.0607). Significant correlations were observed for PFS vs. ECOG (p 


In older mCRC patients, ECOG is a strong predictive marker for treatment duration and PFS, mainly driven by patients with ECOG ≥ 2. In the large group of patients with ECOG ≤ 1, MNA is a predictive marker for PFS.

Clinical trial identification


Legal entity responsible for the study

Roche NV/SA Belgium


Roche NV/SA Belgium


All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings